Bayer’s Aspirin/Phytosterols Combination May Draw FDA Warning
This article was originally published in The Tan Sheet
Executive Summary
Bayer could receive a warning letter for its Aspirin with Heart Advantage OTC/supplement combination product if the agency maintains its historic hard line on combining nonprescription drugs with supplements
You may also be interested in...
Congress Presses FDA To Speak Up On OTC/Supplement Combo Products
Congressional interest turns up the pressure on FDA to make a statement on Bayer Aspirin with Heart Advantage, and issue a definitive policy on any products that combine dietary supplement and OTC drug ingredients
Will Bayer Supplement-Drug Combo Draw Other Firms Into New Market?
FDA's silence about Bayer's launch of Aspirin with Heart Advantage could speak volumes about a possible new marketing opportunity
OTC/Dietary Supplement Combos Cited In FDA Warning Letters
The presence of acetaminophen in OTC/dietary supplement combination products renders them drugs, FDA says in recent warning letters to two companies.